Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
IPO Year: 2014
Exchange: NASDAQ
Website: agiletherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/3/2021 | $3.50 → $2.50 | Buy | HC Wainwright & Co. |
| 9/13/2021 | $7.00 → $3.50 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $6.00 → $5.00 | Outperform | RBC Capital |
RW - AGILE THERAPEUTICS INC (0001261249) (Filer)
EFFECT - AGILE THERAPEUTICS INC (0001261249) (Filer)
EFFECT - AGILE THERAPEUTICS INC (0001261249) (Filer)
EFFECT - AGILE THERAPEUTICS INC (0001261249) (Filer)
S-8 POS - AGILE THERAPEUTICS INC (0001261249) (Filer)
S-8 POS - AGILE THERAPEUTICS INC (0001261249) (Filer)
S-8 POS - AGILE THERAPEUTICS INC (0001261249) (Filer)
S-8 POS - AGILE THERAPEUTICS INC (0001261249) (Filer)
S-8 POS - AGILE THERAPEUTICS INC (0001261249) (Filer)
S-8 POS - AGILE THERAPEUTICS INC (0001261249) (Filer)
Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. ("Agile") (OTCQB:AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. ("Insud") a global pharmaceutical group based in Spain with a 45-year track record and a presence in over 50 countries. The former holders of Agile common stock voted to approve the acq
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. ("Agile") (OTCQB:AGRX), a women's healthcare company, today announced that it has entered into a definitive merger agreement ("Merger Agreement") with
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three and twelve months ended December 31, 2023 and provided a corporate update. "2023 was a year for Agile that we believe demon
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder's equity of at least $2,500,000. Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on March 26, 2024.
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference CallDateThursday, March 28, 2024Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference CallDateFriday, March 22, 2024Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics we
PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile" or the "Company"), a women's healthcare company, today announced that it has paid-off the remainder of its debt facility with Perceptive Advisors ("Perceptive"). This significant milestone completes the repayment schedule contemplated by the Loan Agreement between the Company and Perceptive, which originated in 2020 and ended as of March 11, 2024. The Company remains focused on growing Twirla® and advancing the Company's business plan. "Eliminating the entirety of our debt with Perceptive is a pivotal moment for us, signaling our readiness to embrace new opportunities while continuing to ex
New York, United States, March 12, 2024 (GLOBE NEWSWIRE) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases (STDs), the transmission of sexually transmitted infections (STIs), family planning, and birth control. The use of contraceptive drugs and emergency contraceptives, especially among adolescents, and an increase in awareness of sexually transmitted infections (STIs) are the primary factors driving the expansion of the global contraceptive drug market. The growing acceptance of oral contraceptives as an effective method of birth control and their popularity have contributed to the rise in contraceptive demand, especiall
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-271249 and 333-264960) and Form S-1MEF (File No. 3
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
HC Wainwright & Co. reiterated coverage of Agile Therapeutics with a rating of Buy and set a new price target of $2.50 from $3.50 previously
HC Wainwright & Co. reiterated coverage of Agile Therapeutics with a rating of Buy and set a new price target of $3.50 from $7.00 previously
RBC Capital reiterated coverage of Agile Therapeutics with a rating of Outperform and set a new price target of $5.00 from $6.00 previously
RBC Capital Mkts resumed coverage of Agile Therapeutics with a rating of Outperform and set a new price target of $8.00
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three and twelve months ended December 31, 2023 and provided a corporate update. "2023 was a year for Agile that we believe demon
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference CallDateThursday, March 28, 2024Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference CallDateFriday, March 22, 2024Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics we
PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel and ethinyl estradiol) transdermal system, its birth control patch. The company also reiterated its target for full-year 2023 revenue of at least $25 million and to be cash flow positive from operations in the first quarter of 2024. "In the third quarter 2023, we once again achieved all-time highs across several leading indicators, including net revenue, Twirla demand, factory sales and gross margin," Agile Therapeutics' Chair and Chief Ex
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin Grows to 63% in Third Quarter 2023 from 58% in Second Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue of At Least $25 Million Management to Host Conference Call Today, Thursday, November 9, 2023 at 8:30 a.m. ET PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today reported financial results for the three and nine months ended September 30, 2023, and provided a corporate update. "In
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report third quarter 2023 financial results before the market open on Thursday, November 9, 2023. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Third Quarter 2023 Financial Results Conference CallDateThursday, November 9, 2023Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics Second Quarter 2023 Financial Results Conference CallDateWednesday, August 9, 2023Time8:30 a.m. ET / 5:30 a.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agilethe
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth Quarter 2022 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million Management to Host Conference Call Today, Thursday, May 11, 2023 at 4:30 p.m. ET PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2023 and provided a corporate update. "We are pleased to report another successful quarter for Tw
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company's financial results and provide a business update. EventAgile Therapeutics First Quarter 2023 Financial Results Conference CallDateThursday, May 11, 2023Time4:30 p.m. ET / 1:30 p.m. PT A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics
Appointment of Experienced HR Executive Suzanne Hinchcliffe to Chief People Officer Continues Buildout of Experienced Leadership Team GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Suzanne Hincliffe as Chief People Officer. This announcement follows the recent appointments of several industry veterans to CPSI, Mark Sirgo as Chief Executive Officer, Ernie De Paloantonio as Chief Financial Officer, Kevin Ostrander as Chief Business Officer a
Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer. Appointment of Ernie De Paloantonio to
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,
Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla® James Tursi, M.D. Resigns from Board of Directors PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system growth. As part of the changes, the Company announced the appointment of Amy Welsh to Chief Commercial Officer effective November 1, 2022. Additionally, James P. Tursi, M.D. h
PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that Josephine Torrente has been appointed to the Company's board of directors, as a Class II director, effective as of October 7, 2021. Ms. Torrente will serve on Agile's Science and Technology Committee and Nominating and Corporate Governance Committee. "Josephine is a keen regulatory strategist with extensive experience guiding new drug therapies through the FDA approval process. She also has extensive experience helping companies and investors evaluate pipelines and acquisitions. We are confident that her unique regulatory insights and strategic pers
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.51) by 23.53 percent. The company reported quarterly sales of $5.72 million which beat the analyst consensus estimate of $3.75 million by 52.35 percent. This is a 49.91 percent increase over sales of $3.81 million the same period last year.
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.
Agile Therapeutics (OTC:AGRX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:05 AM. Here's what investors need to know about the announcement. Earnings Agile Therapeutics missed estimated earnings by -59.0%, reporting an EPS of $-1.46 versus an estimate of $-0.92. Revenue was down $381 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.37 which was followed by a 2.0% drop in the share price the next day. Here's a look at Agile Therapeutics's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -1.84 -3.48 -7.50 -11.5 EPS Actual -1.47 -3.10 -7.76 -9 Revenue Estimate 5.27M 4.68M 3.40M 3.
Agile Therapeutics (NASDAQ:AGRX) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement. Analysts estimate that Agile Therapeutics will report an earnings per share (EPS) of $-0.92. Agile Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.37, which was followed by a 2.44% dr
Agile Therapeutics Inc (OTC:AGRX) shares are trading lower by 61% to $0.24 during Tuesday’s session after the company announced the suspension of its trading on the Nasdaq effective Tuesday. The company received a final delisting notice from Nasdaq due to its failure to meet the minimum stockholders’ equity requirement. As a result, trading of its common stock on Nasdaq was suspended effective March 26. However, the company’s shares will still be publicly traded on the over-the-counter market operated by the OTC Markets Group Inc. under the symbol AGRX. Agile Therapeutics added and emphasized that this transition will not impact its business operations and reaffirms its commitment to
Gainers Stoke Therapeutics (NASDAQ:STOK) shares increased by 77.7% to $11.55 during Monday's after-market session. The company's market cap stands at $515.7 million. As per the news, the Q4 earnings report came out today. OpGen (NASDAQ:OPGN) shares moved upwards by 66.61% to $0.79. The market value of their outstanding shares is at $7.9 million. Universe Pharmaceuticals (NASDAQ:UPC) stock rose 11.62% to $1.92. The company's market cap stands at $7.0 million. Vaxxinity (NASDAQ:VAXX) shares moved upwards by 7.99% to $0.72. The company's market cap stands at $90.8 million. Unity Biotechnology (NASDAQ:UBX) stock rose 7.39% to $1.7. The market value of their outstanding shares is at $28.4 mi
Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on March 26, 2024. Effective March 26, 2024, the Company's common stock will be eligible for quotation and trading on the "over the counter" market operated by the OTC Markets Group Inc. (the "OTC Market").
Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share on revenue of $9.20 million. • 51 Talk Online Education (AMEX:COE) is projected to report earnings for its fourth quarter. • Star Equity Hldgs (NASDAQ:STRR) is likely to report quarterly loss at $0.08 per share on revenue of $9.15 million. • Hyzon Motors (NASDAQ:HYZN) is likely to report earnings for its fourth quarter. • Humacyte (NASDAQ:HUMA) is estimated to report quarterly loss at $0.24 per share on revenue of $60 thousand. • AstroNova (NASDAQ:ALOT) is likely to report earnings for its fourth quarter. • Sunlands Technology (NYSE:STG) is likely to report earn
Agile Therapeutics (NASDAQ:AGRX) is set to give its latest quarterly earnings report on Friday, 2024-03-22. Here's what investors need to know before the announcement. Analysts estimate that Agile Therapeutics will report an earnings per share (EPS) of $-0.54. Agile Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.37, which was followed by a 2.44% drop